| Original language | English (US) |
|---|---|
| Pages (from-to) | 1130-1133 |
| Number of pages | 4 |
| Journal | Journal of the American Academy of Dermatology |
| Volume | 87 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 2022 |
ASJC Scopus subject areas
- Dermatology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American Academy of Dermatology, Vol. 87, No. 5, 11.2022, p. 1130-1133.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Clinical characteristics and misdiagnosis of pyoderma gangrenosum of the head and neck
T2 - A retrospective study
AU - Reese, Ashley M.
AU - Gupta, Angela S.
AU - Latour, Emile
AU - Loyo, Myriam
AU - Kaffenberger, Benjamin
AU - Creadore, Andrew
AU - Mostaghimi, Arash
AU - Seminario-Vidal, Lucia
AU - Rick, Jonathan
AU - Ortega-Loayza, Alex G.
N1 - Funding Information: Dr Ortega-Loayza has served on advisory boards for Janssen, BMS, and Boehringer Ingelheim and as a consultant for Genentech and Guidepoint; he has also received research grants from Eli Lilly and Company, OHSU School of Medicine Gerlinger research award, and Medical Research Foundation of Oregon. Dr Kaffenberger has received research funding from the Dermatology Foundation, Eli Lilly and Company, and InflaRx. Dr Mostaghimi has received consulting fees from Pfizer, hims, Digital Diagnostics, Concert, Eli Lilly and Company, AbbVie, and Bioniz. He has served on medical advisory boards for and holds equity in hims and Figure 1 . Dr Mostaghimi has received licensing/royalties from Pfizer and Concert and has participated in clinical trials by Eli Lilly and Company and Concert. Additionally, he serves as an associate editor for JAMA Dermatology. Dr Seminario-Vidal has had advisory board relationships with Novartis, Boehringer Ingelheim, Helsinn, Kyowa Kirin, Regeneron, and Blueprint. She or her institution received research funding from Eli Lilly and Company, Soligenix, Helsinn, Eisai, Boehringer Ingelheim, Novartis, AbbVie, BMS, Celgene, Glenmark, Kyowa Kirin, Amgen, AnaptysBio, and Innate Pharma. Dr Seminario-Vidal has also been a speaker for Helsinn and Kyowa Kirin. Authors Reese and Latour and Drs Gupta, Loyo, Creadore, and Rick have no conflicts of interest to declare.
PY - 2022/11
Y1 - 2022/11
UR - http://www.scopus.com/inward/record.url?scp=85123468552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123468552&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2022.02.008
DO - 10.1016/j.jaad.2022.02.008
M3 - Article
C2 - 35151756
AN - SCOPUS:85123468552
SN - 0190-9622
VL - 87
SP - 1130
EP - 1133
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 5
ER -